Welcome, Introduction, Polling Questions
Introduction: Novel ADCs for Treatment of NSCLC – Professor Smit
Activity of ADCs in Clinical Trials for Lung Cancer
- HER2-altered NSCLC, HER3-positive NSCLC – Dr. Yu
- TROP-2–positive NSCLC, CEACAM5, c-Met–positive NSCLC – Dr. Planchard
Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC
Summary, Final Thoughts, Audience Q&A
Date / Time
Egbert F. Smit, MD, PhD
Department of Pulmonary Diseases
Leiden University Medical Center
Department of Thoracic Oncology
Netherlands Cancer Institute
David Planchard, MD, PhD
Associate Professor of Medicine
Department of Medicine at Gustave Roussy
Helena Yu, MD
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
The goal of this activity is to improve the knowledge and competence of learners to integrate new and emerging prognostic and predictive biomarkers into NSCLC treatment paradigms.
This program is intended for global medical oncologists, pathologists and other healthcare providers who care for patients with lung cancer.
Upon completion of this activity, participants should be able to:
- Discuss the clinical rationale for assessing HER2, HER3, and TROP2 in the metastatic setting for NSCLC
- Appraise the available clinical data on HER2-, HER3-, and TROP2-targeted antibody–drug conjugates in NSCLC
- Plan therapeutic strategies for appropriate patients with HER2-altered NSCLC
- Identify patients eligible to enroll on important ongoing clinical trials based evaluating novel HER2-, HER3-, and TROP2-targeted therapies in breast, gastrointestinal, and lung cancers
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.